SCHEMBL21363515

SCHEMBL21363515

N/C(=N/OC(=O)CCl)[C@@H]1CO[C@@H](c2ccc(Cl)cc2)C1

nearest known ligand 0.38

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
SLC9A1 P19634 1/20 0.38
TDP1 Q9NUW8 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.34
L3MBTL1 Q9Y468 4/20 0.33
HTT P42858 2/20 0.33
TRPA1 O75762 4/20 0.33
LMNA P02545 1/20 0.32
SLC6A2 P23975 1/20 0.32
SLC6A4 P31645 1/20 0.32
SLC6A3 Q01959 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21353891 1.00 SLC9A1 (0.38) SLC9A1TDP1SMN1; SMN2L3MBTL1HTT
SCHEMBL21353888 1.00 SLC9A1 (0.38) SLC9A1TDP1SMN1; SMN2L3MBTL1HTT
SCHEMBL28483131 0.89 SLC9A1 (0.37) SLC9A1L3MBTL1TRPA1
SCHEMBL21363706 0.89 SLC9A1 (0.37) SLC9A1L3MBTL1TRPA1
SCHEMBL28483130 0.89 SLC9A1 (0.37) SLC9A1L3MBTL1TRPA1
SCHEMBL21353835 0.89 SLC9A1 (0.37) SLC9A1L3MBTL1TRPA1
SCHEMBL28725165 0.81 SLC9A1 (0.42) SLC9A1TDP1SMN1; SMN2L3MBTL1HTT
SCHEMBL22209882 0.81 SLC9A1 (0.42) SLC9A1TDP1SMN1; SMN2L3MBTL1HTT
SCHEMBL21353889 0.79 TRPA1 (0.33) TRPA1SLC6A2SLC6A4SLC6A3
SCHEMBL21353961 0.78 SLC9A1 (0.39) SLC9A1L3MBTL1TRPA1SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11655245-B2 Oxadiazole transient receptor potential channel inhibitors GENENTECH, INC. (US) 2023-05-23 US disclosed
US-11655245-B2 Oxadiazole transient receptor potential channel inhibitors GENENTECH, INC. (US) 2023-05-23 US disclosed
US-20230121700-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS GENENTECH, INC. (US) 2023-04-20 US disclosed
US-20200308161-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS GENENTECH, INC. (US) 2020-10-01 US disclosed
US-10710994-B2 Oxadiazole transient receptor potential channel inhibitors GENENTECH, INC. (US) 2020-07-14 US disclosed
WO-2019182925-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS GENENTECH, INC. (US) 2019-09-26 WO disclosed
US-20190284179-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS GENENTECH, INC. (US) 2019-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11655245-B2 Oxadiazole transient receptor potential channel inhibitors TRPA1, TRPV1, P2RX3 SLC9A1 152/4885TDP1 1706/4885SMN1; SMN2 1218/4885
US-20190284179-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS TRPA1, TRPV1, TRPV3 SLC9A1 204/4885TDP1 1591/4885SMN1; SMN2 1161/4885
US-20200308161-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS TRPA1, TRPV1, P2RX3 SLC9A1 152/4885TDP1 1706/4885SMN1; SMN2 1218/4885
US-10710994-B2 Oxadiazole transient receptor potential channel inhibitors TRPA1, TRPV1, TRPV3 SLC9A1 204/4885TDP1 1591/4885SMN1; SMN2 1161/4885
US-20230121700-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS TRPA1, TRPV1, TRPV3 SLC9A1 204/4885TDP1 1591/4885SMN1; SMN2 1161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.